[Neurochemical mechanisms of the development of motion sickness].
D000818:Animals; D001127:Arginine Vasopressin / Q000627:therapeutic use; D001679:Biogenic Amines / Q000378:metabolism*; D002415:Cats; D004195:Disease Models, Animal; D008297:Male; D008959:Models, Neurological; D009041:Motion Sickness / Q000188:drug therapy / Q000209:etiology*; D012601:Scopolamine / Q000627:therapeutic use; D014725:Vestibular Nerve / Q000187:drug effects / Q000378:metabolism*; D014726:Vestibular Nuclei / Q000187:drug effects / Q000378:metabolism*; D014722:Vestibule, Labyrinth / Q000187:drug effects / Q000294:innervation / Q000378:metabolism*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D001679:Biogenic Amines; D001127:Arginine Vasopressin; D005680:gamma-Aminobutyric Acid; D012601:Scopolamine
Neĭrokhimicheskie mekhanizmy vozniknoveniia bolezni dvizheniia.